Berberine vs Survodutide
A side-by-side research comparison of Berberine and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Berberine | Survodutide |
|---|---|---|
| Full name | Berberine HCl | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | OTC supplement | Phase 3 Clinical Trial |
| Mechanism | Activates AMP-activated protein kinase (AMPK), the cellular energy sensor, improving insulin sensitivity, reducing hepatic glucose production, lowering LDL cholesterol, and favorably shifting the gut microbiome. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 371.81 Da | 4,500 Da (approximate) |
| Half-life | ~2.5 hours (poor systemic bioavailability) | 5-7 days |
| Bioavailability | Low (~5%); improved by dihydroberberine or piperine | High (SubQ) |
| Typical dose | 500 mg, 2-3x per day | 0.6-6.0 mg |
| Frequency | 2-3x daily with meals | Once weekly |
| Route | Oral capsule | Subcutaneous |
Berberine reported benefits
- Improved insulin sensitivity
- Lower fasting blood glucose
- Reduced LDL and triglycerides
- AMPK activation (exercise-mimetic)
- Gut microbiome support
- Modest weight/waist reduction
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.